From: Prognostic factors in patients with loco-regionally advanced gastric cancer
Variables | 2000–2004 | 2005–2009 | Total |
---|---|---|---|
Number of patients included | 73 | 47 | 120 (100%) |
Median age in years (range) | 71 (26–91) | 68 (41–90) | 70.5 (26–91) |
Gender | |||
 Female | 34 | 21 | 55 (46%) |
 Male | 39 | 26 | 65 (54%) |
Karnofsky performance status | |||
 100 | 32 | 20 | 52 (43%) |
 90 | 13 | 13 | 26 (22%) |
 10–80 | 28 | 14 | 42 (35%) |
Loco-regionally advanced cancer | |||
 Synchronous | 47 | 33 | 80 (67%) |
 Metachronous | 26 | 14 | 40 (33%) |
Morphological type | |||
 Signet ring cells (SRS) | 18 | 19 | 37 (31%) |
 Adenocarcinoma without SRS | 48 | 27 | 75 (63%) |
 Linitis plastica | 1 | 0 | 1 (1%) |
 Missing data | 6 | 1 | 7 (6%) |
Differentiation | |||
 Poorly differentiated | 48 | 36 | 84 (70%) |
 Moderately differentiated | 13 | 4 | 17 (14%) |
 Well-differentiated | 1 | 1 | 2 (2%) |
 Missing data | 11 | 6 | 17 (12%) |
Lauren’s classification | |||
 Intestinal type | 17 | 14 | 31 (26%) |
 Gastric type | 1 | 1 | 2 (2%) |
 Diffuse type | 22 | 12 | 34 (28%) |
 Mixed type | 0 | 2 | 2 (2%) |
 Missing data | 33 | 18 | 51 (43%) |
Distant metastasis | |||
 No | 45 | 26 | 71 (59%) |
 Yes | 28 | 21 | 49 (41%) |
  Synchronous | 18 | 16 | 34 (28%) |
  Metachronous | 10 | 5 | 15 (12%) |
Palliative treatment | |||
 Chemotherapy | 33 | 20 | 53 (44%) |
 Radiotherapy | 0 | 2 | 2 (2%) |
 Chemoradiotherapy | 5 | 2 | 7 (6%) |